• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease

    2018-05-05 06:47:13MinChenZhiYunDuXiZhengDongLiLiRenPingZhouKunZhang
    關(guān)鍵詞:履歷表小景段位

    Min Chen, Zhi-Yun Du, Xi Zheng, , Dong-Li Li , Ren-Ping Zhou Kun Zhang, ,

    1 Institute of Natural Medicinal Chemistry & Green Chemistry, College of Light Industry and Chemical Engineering, Guangdong University of Technology, Guangzhou, Guangdong Province, China

    2 Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

    3 Wuyi University, Jiangmen, Guangdong Province, China

    4 International Healthcare Innovation Institute (Jiangmen), Jiangmen, Guangdong Province, China

    Introduction

    Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder prevalent worldwide, yet with no effective cure. It affects about 35 million individuals and cost more than $226 billion in 2016 alone. A conservative estimate of its prevalence is one in nine people aged 65 years and older, being almost three times higher for people aged 85 and older (Alzheimer’s Association, 2015). By 2050, a new case of AD is expected to develop every 33 seconds(Lopez, 2011). Indeed, AD is now imposing a tremendous impact on society and is a costly burden that will be a modern epidemic in the near future (Hampel et al., 2011).Consequently, there is an urgent need for global diagnostic,preventive, and therapeutic measures to control the impact of this devastating disease.

    Like other chronic diseases, AD develops as a result of multiple factors rather than a single cause. However, its etiology and pathology remain unclear (LaFerla and Green,2012). Clinically, AD is characterized by memory and cognitive impairments, and personality and behavior changes(Huang and Mucke, 2012). The pathological hallmarks observed in AD brain include extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs). Amyloid-β(Aβ) is generated a cleavage of the amyloid precursor protein by β- and γ-secretases. This results in native Aβ monomers that have prosurvival effects on neurons and protect mature neurons against excitotoxic death (Giuffrida et al.,2009). In contrast, under pathological conditions, excessive accumulation of monomers results in their assembly into soluble, diffusible toxic oligomeric Aβ species: low-molecular-weight aggregates consisting of 2–30 Aβ peptides. When the oligomers reach a critical concentration, they form insoluble fibrils/aggregates and plaques. It is important to note that soluble Aβ oligomers are more toxic than insoluble deposits (Verma et al., 2015). In particular, Aβ dimers (the major form of soluble oligomers isolated from AD cortex)directly induce tau hyperphosphorylation and neurite degeneration (Jin et al., 2011). NFTs are another hallmark of AD, and are composed of hyperphosphorylated tau, which disrupts microtubules and impairs axonal transport (Beharry et al., 2014; Metaxas and Kempf, 2016; Ye et al., 2017). In addition to these pathologies, extensive neuroinflammation and oxidative damage are also observed at sites of neurodegeneration. Indeed, these pathological factors act together,resulting in progressive neuronal damage and cognitive deficits. Importantly, a vicious cycle develops among Aβ,NFTs, oxidative stress, and inflammation. Aβ and NFTs activate microglia and induce production of reactive oxygen species and inflammatory factors. Conversely, reactive oxygen species and inflammatory cytokines directly act on neurons, further promoting Aβ and NFT formation (Glass et al., 2010; Broussard et al., 2012; Luque-Contreras et al.,2014). Therefore, seeking effective therapeutics with multiple targets is highly desirable (Frautschy and Cole, 2010).Fortunately, accumulating evidence suggests that curcumin(1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) may play a significant role in AD therapy, exerting pleiotropic properties. Curcumin can directly bind to Aβ in the central nervous system and prevent its assembly into neurotoxic species (Kozmon and Tvaro?ka, 2015; Rao et al.,2015). In addition, curcumin can reduce oxidative stress and inflammatory responses, and has beneficial effects on neuronal and vascular functions (DiSilvestro et al., 2012). Extensive lines of evidence indicate that Aβ oligomer production,oxidative markers, and neuroinflammation are attenuated by administration of curcumin (Hu et al., 2015; Nasir Abbas Bukhari and Jantan, 2015).

    This review discusses the multifaceted functions of curcumin, including its use in diagnosis, prevention, and therapy at different stages of AD.

    Curcumin: a Sensitive Fluorochrome for AD Diagnosis

    Diagnosis of AD in patients is based on clinical examination,which is mainly suitable for late-stage disease (Dubois et al.,2007). Indeed, no definite early diagnostic test at the asymptomatic stage is currently available. The first diagnostic criteria for AD were established in 1984, and included progressive deterioration of language, memory, and cognition, as well as progressive cerebral atrophy detectable by brain imaging(Alzheimer’s Association, 2010). However, these criteria were revised as they are too general. The new AD diagnostic criteria now require a gradual onset and fast-progressing cognitive function impairment, which cannot be explained by other diseases (Dubois et al., 2007). Pathological features such as cerebrovascular changes, Aβ, and NFTs, are believed to precede or coexist with AD (Parnetti et al., 2006). Thus, use of biomarkers may increase diagnostic specificity and reliability, which are included in the updated criteria (Reitz et al., 2011). At the time of diagnosis, patients are usually at a mild to moderate stage,which cannot be prevented by current treatments. To overcome this disadvantage, more sensitive diagnostic probes is highly desirable (Bateman et al., 2012; Chase, 2014).

    With its recent success as a “multi-anti” agent, curcumin has attracted considerable interest from researchers in the fields of physics, chemistry, biology, and medicine. Curcumin comprises two phenols connected by a linear β-diketone linker, which also induces keto–enol tautomerism. Because of its special structure, curcumin exhibits many interesting photophysical and photochemical properties (Priyadarsini,2009). Curcumin effectively binds to Aβ plaques and emits a strong fluorescence signal, making it a powerful diagnostic reagent for AD (Garcia-Alloza et al., 2007). During the last two decades, extensive research has been performed to develop curcumin probes for targeting Aβ with available imaging modalities, including positron emission tomography (PET),two-photon microscopy, magnetic resonance imaging (MRI),and near-infrared fluorescence (NIRF) (Tu et al., 2015).

    PET

    PET imaging with Aβ-specific tracers has been widely applied in clinical trials, with three Aβ PET tracers approved by the US Food and Drug Administration for clinical use:

    18F-flutemetamol (Vizamyl),18F-florbetapir (Amyvid), and

    18F-florbetaben (Neuraceq). Moreover, this approach is an emerging tool for AD research and numerous new PET probes are under development (Mathis et al., 2012). Curcumin derivatives can be labeled with radioactive nuclides(including several radioiodinated ligands and18F fluoropegylated ligands), making it applicable for PET (Cui et al.,2011). Ryu et al. (2006) synthesized fluoropropyl-substituted curcumin (Figure 1A), which shows high binding affinity(Ki = 0.07 nM) to Aβ. Furthermore, its radiolabeled form shows suitable lipophilicity and reasonable brain uptake.These results suggest that18F fluoropropyl-substituted curcumin is a promising radioligand for imaging Aβ. In addition, Rokka and coworkers synthesized the [18F]curcumin derivative (Figure 1A), with high binding affinity to Aβ plaques in transgenic APP23 mouse brain cryosections.Studies have demonstrated that18F curcumin derivative can be efficiently removed from blood (1–5 minutes), but has low blood-brain barrier (BBB) penetration, with18F-radioactivity concentrations of only 0.04% ID/g in mouse brain and 0.03% ID/g in rat brain (Rokka et al., 2014). To overcome this low BBB permeability, Mourtas et al. (2014) designed a lipid-polyethylene glycol (PEG)-curcumin derivative to increase BBB penetration and fluorescence intensity. These nanoliposomes were loaded with curcumin derivative and immobilized to a BBB transport mediator (monoclonal anti-transferrin antibody [MAb]). As anticipated, these multifunctional nanoliposomes were more efficient at labeling Aβ deposits in postmortem tissue of AD patients, with fluorescence was enhanced by almost six times. Uptake of MAb-decorated nanoliposomes loaded with curcumin-derivative was increased (almost two-fold) compared with curcumin-conjugated nanoliposomes (Mourtas et al., 2014).Altogether, these findings indicate that curcumin derivatives entrapped in multifunctional nanoliposomes represent a useful approach in AD diagnosis.

    Figure 1 Curcumin is a sensitive fluorochrome for AD diagnosis.

    Two-photon microscopy

    Two-photon microscopy is an important technique for investigating Aβ species, and provides insight into the dynamics of individual plaque expansion and disruption of the microenvironment (Condello et al., 2011). Zhang et al. (2014)designed and synthesized CRANAD-28 (Figure 1B) by introducing a pyrazole ring into curcumin. With this replacement, CRANAD-28 improved tissue penetration because of its longer excitation (498 nm) and emission (578 nm), and displayed high quantum yield in both phosphate-buffered saline (PBS) (0.32) and ethanol (> 1.00). When tested in vitro towards different Aβ species, CRANAD-28 showed high affinity, withKd values ranging from 52.40 to 162.90 nM.In vivotwo-photon microscopy clearly demonstrated that CRANAD-28 not only labeled Aβ plaques and cerebral amyloid angiopathies in 9-month old APP/PS1 mice, but also attenuated Aβ crosslinking in brain. These results suggest the potential use of CRANAD-28 in both diagnosis and therapy for AD (Zhang et al., 2014).

    “說完了陣容,我們來看一下參賽選手的段位?!蓖跣【皝砭窳?,來到雙方海軍將領(lǐng)的履歷表前,“都是正在努力向‘王者’歐美學(xué)習(xí)的‘青銅’段位選手,算是新手互毆。既然是新手互毆,技術(shù)上的看點(diǎn)不多,有時(shí)還得看點(diǎn)運(yùn)氣!”

    MRI

    Figure 2 Curcumin: a pleiotropic agent for treatment of Alzheimer’s disease.

    MRI is cheaper, easier, and nonradioactive in comparison with PET, but its sensitivity needs to be improved before it can be used clinically. Fortunately, recent studies have tested curcumin derivatives as MRI probes for Aβ imaging. Yanagisawa et al. (2011) developed a perfluoro curcumin analog,FMeCl (Figure 1C), for19F MRI to facilitate visualization of Aβin vivo.They found that compared with wild-type mice,19F MRI showed marked19F signal levels in the brain of Tg2576 mice after injection of FMeCl (200 mg/kg). Moreover,19F signal in Tg2576 mice aligned with the distribution of Aβ deposits (Yanagisawa et al., 2011). Interestingly, FMeCl not only labeled Aβ plaques, but also inhibited Aβ aggregates,glial cell activity, and cognitive deficits in APP/PS1 mice(Yanagisawa et al., 2015). Subsequently, a new formulation of FMeCl was developed to increase its bioavailability. Thus,FMeCl may be a promising theranostic agent owing to its dual role in imaging and therapy, similar to CRANAD-28.In addition to curcumin analogues, several curcumin-conjugated nanoparticles have been approved for early diagnosis of AD (Patil et al., 2015). Cheng et al. (2015) used magnetic nanoparticles (MNPs) comprised of super paramagnetic iron oxide conjugated to curcumin to develop a nanoimaging agent (Cur-MNPs). Cur-MNPs show low cytotoxicity (up to 167 mg/mL) and considerable BBB penetration potential. Many dark spots were found by MRI in Tg2576 brainin vivo, while almost no such spots were found in control brain. Therefore, Cur-MNPs are another successful example of nanoparticles for Aβ imaging (Cheng et al., 2015).

    NIRF

    NIRF is an attractive tool for early AD detection, and presents several advantages including acceptable photon pene-tration, noninvasive exposure, and inexpensive instrumentation. In past years, Ran’s group has designed and synthesized a series of curcumin analogues (CRANAD-X) as NIRF imaging probes (Ran et al., 2009). First, they synthesized CRANAD-1 (Figure 1D) by introducing a difluoroboronate ring into curcumin. With this replacement, CRANAD-1 emission was red-shifted to λmax (em) = 560 nm in methanol, which is not in the NIRF wavelength range (> 650 nm).To further increase emission wavelength, CRANAD-1 was modified by substituting the N,N′-dimethyl group for a phenolic hydroxyl group to yield the compound, CRANAD-2,(Figure 1D). As anticipated, CRANAD-2 showed longer emission at λmax (em) = 760 nm.In vitro, CRANAD-2 effectively interacted with Aβ (Kd = 38.00 nM) and increased fluorescence brightness by 70-fold.In vivo, CRANAD-2 showed a significant fluorescence difference between 19-month-old wild-type and transgenic mice. However, as a limitation, CRANAD-2 was not able to detect soluble dimeric and oligomeric Aβ species, which are more neurotoxic than insoluble deposits. To overcome this limitation, Ran et all. (2009) designed and synthesized another curcumin analogue, CRANAD-58 (Figure 1D), which detects both insoluble and soluble Aβ species. As expected, CRANAD-58 not only displayed sufficient long emission (750 nm), but also exhibited strong binding to soluble Aβ monomers. Notably,CRANAD-58 detected soluble Aβ species in 4-month-old APP/PS1 mice, a younger age than with CRANAD-2. Consequently, CRANAD-58 can be considered the first NIRF imaging probe that is sensitive to both soluble and insoluble Aβ speciesin vitroandin vivo. Importantly, Aβ imaging is not only a means for early diagnosis, but also an approach for monitoring the efficacy of therapy. However, none of these NIRF probes have been used for this purpose. To fill this gap, Ran et al. (2009) designed CRANAD-3 (Figure 1D)by replacing the two aromatic rings with pyridyls to increase Aβ affinity.In vitrospectral testing andin vivoNIRF imaging indicated that CRANAD-3, like CRANAD-58, was sensitive to both soluble and insoluble Aβ, but with higher sensitivity than CRANAD-58. Crucially, owing to its excellent ability to detect both soluble and insoluble Aβ, CRANAD-3 can be used to monitor the effectiveness of Aβ-lowering therapeutics, suggesting a dual role of CRANAD-3 in AD(Ran et al., 2009; Zhang et al., 2013, 2015).

    Table 1 Clinical trials with curcumin in diagnosis, prevention, and therapy

    Compared with traditional diagnostic agents, synthesized

    curcumin analogues (CRANAD-58 and CRANAD-3) can detect not only insoluble Aβ plaques but also soluble Aβ oligomersin vitroandin vivo(Zhang et al., 2013, 2015).Moreover, CRANAD-3 can monitor and evaluate the effectiveness of anti-amyloid interventions, enabling selection of patients for treatment (Zhang et al., 2015). Importantly,curcumin analogues (CRANAD-28 and FMeC1) combine diagnostic and therapeutic properties in a single molecule(Yanagisawa et al., 2011; Zhang et al., 2014), leading to time-saving and cost-effective optimization. Apart from the theranostic role of curcumin for Aβ, curcumin has been reported to detect tau pathology. For example, Mohorko et al.(2010) have shown that curcumin can label tau aggregates in brain sections that coincides with routine thioflavine S and Gallyas silver staining. This suggests curcumin has diagnostic potential in tauopathies. Similarly, Park et al. (2015)designed and synthesized a novel curcumin-based molecular probe by introducing a (4-dimethylamino-2,6-dimethoxy)phenyl moiety to the aromatic rings of CRANAD-2. This probe showed a significant fluorescence response to tau fibrils (quantum yield = 0.32;Kd = 0.77 μM; λmax(em) = 620 nm), encouraging further development of curcumin in AD theranostics for both Aβ and NFTs.

    Table 2 Commercial formulations of curcumin

    Curcumin: a Health-Promoting Nutraceutical for AD Prevention

    At present, there is no cure for AD, yet the impact of this disease can be lessened by delaying its onset. Delayed onset of 6 months would result in a reduction of 100,000 cases after 10 years, highlighting the importance of prevention(Brookmeyer et al., 1998). Epidemiological and experimental data suggest that optimal diet, physical exercise,and intellectual activity may promote brain health (Vivar,2015). In particular, an optimal diet with rich phenolic compounds may provide preventive effects on development of AD (Yamada et al., 2015). Safouris et al. (2015) reported that consumption of a Mediterranean-type diet reduced the incidence of AD. This diet is characterized by a high proportion of plant foods and fish, a moderate proportion of wine,and a low proportion of red meat. They found that higher adherence to the Mediterranean-type diet was associated with lower risk for AD (hazard ratio of 0.60, compared with 0.91 in non-Mediterranean countries) (Safouris et al., 2015).Similarly, Ng et al. (2006) reported that consumption of an Asian-type diet that is rich in soy and turmeric (containing considerable amounts of isoflavones and curcumin, respectively) and high levels of seaweed, also reduced the incidence of AD. These diets are rich in fruits and vegetables, which are primary sources of dietary polyphenols, glucosinolates,and vitamins. Curcumin is a natural phenolic substance with beneficial effects on various chronic conditions including obesity, diabetes, and depression (Arun and Nalini, 2002;Kim and Kim, 2010; Rinwa et al., 2013). Importantly, such chronic diseases may be risk factors for AD, and are linked to the etiology or outcome of AD (Jorm, 2001; Gustafson et al., 2003). For example, diabetes promotes the formation of advanced glycosylation end products, leading to activation of receptors for advanced glycosylation end products on the surface of glial cells, vascular endothelial cells, and neurons. In turn, this induces inflammatory responses and increases Aβ influx, giving rise to further brain damage and ensuing cognitive impairment (Yan et al., 1996). This suggests that curcumin intake may prevent AD progression by reducing AD risk(Reitz et al., 2011). Additionally, curcumin improves memory function in healthy-aged rodents by enhancing synaptic plasticity and neurogenesis (Kim et al., 2008; Dong et al., 2012;Belviranl? et al., 2013). It may also increase docosahexaenoic acid synthesis, resulting in better plasma membrane integrity,which further maintains normal mitochondrial and synaptic function (Pinkaew et al., 2015; Wu et al., 2015). Several studies have examined curcumin supplementation in healthy older people. DiSilvestro et al. (2012) demonstrated that a low dose of lipidated curcumin produced diverse potential health benefits in healthy middle-aged people by increasing nitric oxide levels and lowering soluble intercellular adhesion molecule.Both molecules have relevance for cardiovascular disease risk.Also, curcumin suppressed alanine aminotransferase activity,a general marker of liver injury, and raised plasma myeloperoxidase, an effect associated with inflammation (DiSilvestro et al., 2012). More recently, Cox et al. (2015) showed that supplementation with solid lipid curcumin formulation (80 mg as Longvida?) improved cognitive function, reduced fatigue,and lessened the detrimental impact of psychological stress on mood, which may improve quality of life for the growing elderly population. Therefore, dietary uptake of curcumin may reduce AD risk, enhance cognitive function, and delay and counteract the effect of aging and neurodegenerative disease.

    Curcumin: a Pleiotropic Agent for AD Treatment

    Considering the multifactorial etiology and complex pathological mechanisms involved in AD, it is quite reasonable that treatments targeting a single causal or modifying factor will have limited benefits (Figure 2). Therefore, growing interest is focused on therapeutic agents with pleiotropic activity, targeting several affected processes (Bajda et al., 2011).Several compounds described here fulfill these properties,with curcumin showing strong anti-Aβ properties and considerable anti-inflammatory and antioxidant activities (Belkacemi et al., 2011).

    Effect of curcumin on Aβ protein

    Over the past decades, the amyloid hypothesis has been widely accepted and been the focus of AD research (Soto,1999). Consequently, one current strategy for treating AD is anti-amyloid treatments including decreasing Aβ production, inhibiting Aβ aggregation, and promoting Aβ clearance.In vitrostudies have shown that curcumin lowers Aβ levels by attenuating amyloid precursor protein maturation and suppressing beta-secretase 1 (BACE1) expression, which is the sole β-secretase enzyme (Liu et al., 2010). Moreover,in vivostudies using a drosophila AD model have shown that demethoxycurcumin has strong inhibitory BACE-1 activity(IC50= 17 μM), contributing to rescue of morphological and behavioral defects caused by overexpression of amyloid precursor protein maturation and BACE1 (Wang et al., 2014).Recent studies have investigated the molecular mechanism of BACE-1 inhibition by curcumin. Curcumin was found to repress BACE-1 transcription by activating the Wnt/β-catenin pathway, which binds to T-cell factor-4, a repressor of the BACE1 gene (Zhang et al., 2011; Parr et al., 2015). Apart from its role in amyloid precursor protein maturation, studies have indicated that curcumin can attach to Aβ peptides and prevent Aβ aggregationin vitroandin vivo.In vitrocurcumin displays high-affinity binding to Aβ aggregates (Kd= 0.20 nM), with EC50 of curcumin for Aβ destabilization being approximately 1 μM (Ono et al., 2004). In APPswe/PS1dE9 mice, Garcia-Alloza et al. (2007) suggested that curcumin (7.5 mg/kg intravenously, 7 days) clears or reduces the size of senile plaques (Garcia-Alloza et al., 2007).In Tg2576 mice, a daily single dose (500 ppm) of curcumin administered orally for 5 months significantly reduced levels of insoluble Aβ (85%) and Aβ plaques (32.50%) (Yang et al.,2005). Based on comprehensive structure–activity analysis,coplanarity of two phenol rings, length and rigidity of the linker, and substitution conformation of the phenol rings were shown to contribute to the inhibitory potency of curcumin (Reinke and Gestwicki, 2007). Further studies have investigated the atomistic mechanism of curcumin inhibition on Aβ aggregation. By molecular docking and molecular dynamic simulations, Rao et al. (2015) demonstrated that curcumin binding to Aβ-aggregates leads to significant amino acid fluctuations, with a shift in equilibrium towards non-toxic Aβ aggregates. Moreover, curcumin binds to Aβviastrong hydrophobic interactions and H-bonding, which disrupts preformed fibrils and prevents oligomerization(Kundaikar and Degani, 2015). Interestingly, alternative theories suggest that curcumin blocks Aβ aggregation by chelating metal ions, such as Cu2+, Zn2+, and Fe3+, likely agonists of Aβ aggregation and oxidative stress (Perrone et al., 2010; Banerjee, 2014). Kozmon investigated interactions between Aβ peptide and Cu2+ions and/or curcumin by molecular dynamic simulations. They found that curcumin not only chelated Cu2+ions, but also directly attached to Aβ, forming curcumin–Cu2+–Aβ and curcumin–Aβ complexes that decrease toxic β-sheet structures (Kozmon and Tvaro?ka, 2015). Crucially, the effects of curcumin are not limited to modulation of Aβ production and aggregation,and further studies have shown that curcumin accelerates Aβ clearance. Curcumin increases expression of autophagyand lysosome-related protein markers, such as heat shock proteins, LC3A/B-II, and beclin-1, which are essential for Aβ phagocytosis in neurons (Maiti et al., 2017). Moreover,a curcumin derivative, CNB-001, serves as a 5-lipoxygenase inhibitor, inducing activation of the PERK/eIF2/ATF4 arm of the unfolded protein response and accelerating degradation of Aβ aggregates (Valera et al., 2013). These studies not only indicate that curcumin plays a critical role in the Aβ cascade, but also identify several new targets for AD treatment, such as Wnt/β-catenin and PERK/eIF2/ATF4 of the unfolded protein response.

    Effect of curcumin on neuroinflammation

    Neuroinflammation is one of the pathological factors in the vicious circle of AD pathogenesis, and is characterized by extensive glial activation and robust cytokine production at the site of damage. Curcumin targets numerous inflammatory signaling pathways, including biosynthesis and metabolism of arachidonic acid, pattern recognition receptor pathways on the surface of glial cells, and nuclear transcription factors(He et al., 2015). For example, IC50 values of curcumin for secretory phospholipase A2, cyclooxygenases-2, lipo-oxygenase, and microsomal prostaglandin E synthase-1 (which are involved in arachidonic acid metabolism) are 11.10, 93.36,57.77, and 4.88 μM, respectively (Ahmad et al., 2014). Similarly, curcumin serves as a repressor of both toll-like receptors and NOD-like receptors (NLRs), sensors of Aβ and NFTs during neuroinflammation. Curcumin inhibits dimerization of toll-like receptor 4, resulting in marked reduction of proinfl ammatory cytokines (Youn et al., 2006). Recent studies have suggested that curcumin attenuates neurotoxicity and the related inflammatory response by suppressing nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome activation (Gong et al., 2015; Li et al., 2015). Curcumin may also act as an agonist of both peroxisome proliferator-activated receptor γ and nuclear factor erythroid-2 related factor 2, which regulate expression of various inflammatory cytokines (Innamorato et al., 2008;Wang et al., 2010).In vitrostudies suggest that curcumin attenuates Aβ-induced inflammatory responses in microglia by suppressing the ERK1/2 and p38 signaling pathways (Shi et al., 2015). Moreover,in vivostudies using an AD rat model have shown that curcumin exerts a significant reduction in glialfibrillary acidic protein expression and astrocyte activity,contributing to the rescue of behavioral defects caused by Aβ intracerebral injection (Wang et al., 2013). These results imply that the powerful anti-inflammatory properties of curcumin may be responsible for inhibiting glial cell activation and alleviating Aβ pathology in AD.

    Effect of curcumin on oxidative stress

    As described, Aβ and phosphorylated-tau aggregation, inflammation, and oxidative stress form a vicious cycle in the brain, contributing to neuronal apoptosis and cognitive decline in AD. Thus, interventions to attenuate oxidative stress have been postulated as another approach in prevention and treatment of AD. Curcumin has excellent antioxidant properties, which elevate superoxide dismutase and catalase activity to conserve glutathione levels and decrease malonyldialdehyde accumulation in mouse models and humans(Soni and Kuttan, 1992; Soudamini et al., 1992; Ak and Gül?in, 2008; Dkhar and Sharma, 2010). A study using a homocysteine-induced rat aging model showed that curcumin(5, 15, or 45 mg/kg) treatment improved learning and memory function by significantly decreasing malonyldialdehyde and super oxide anion levels in the hippocampus (Ataie et

    al., 2010). However, elevated homocysteine plasma levels also led to abnormal DNA methylation, resulting in decline of cognitive performance (Fux et al., 2005). Curcumin inhibits DNA methyltransferase and may be responsible for its ability to improve cognitive impairment (Fang et al., 2007).Moreover, curcumin inhibits Aβ-induced oxidative stress and cell toxicity, which are dependent on telomerase. Telomerase is a ribonuclear protein complex that synthesizes and elongates telomeric DNA, protecting cells against senescence (Fang et al., 2007). These data suggest that telomerase may be a novel target of curcumin, providing a potential new therapeutic strategy for treating AD.

    Curcumin in the Clinic

    Extensive preclinical studies over the past decades have indicated the therapeutic potential of curcumin against a wide range of human chronic diseases. In addition, curcumin directly interacts with numerous cell signaling molecules such as pro-inflammatory cytokines, apoptotic proteins,and phosphorylase kinases. These studies provide a solid foundation for evaluating the efficacy of curcumin in clinical trials (Gupta et al., 2013). Until now, nine human trials of curcumin in AD interventions (including diagnosis, prevention and therapy) have been performed (Table 1). In diagnosis, a pilot study using curcumin as a fluorochrome for retinal imaging found that curcumin enabled Aβ visualization with excellent fluorescence properties. The retinal Aβ test was able to differentiate between AD and non-AD with 80.6% specificity (Frost et al., 2014). Additionally, Cox et al. (2015) showed that supplementation with solid lipid curcumin formulation (80 mg as Longvida?) improved cognitive function and reduced fatigue and psychological stress in a healthy older population, suggesting a protective potential of curcumin. Nevertheless, clinical studies on mild cognitive impairment and AD found no significant differences in cognitive function and biomarker measurements between placebo and intervention groups, although curcumin increased vitamin E levels and did not cause any adverse effects at a high dose (Baum et al., 2008). These studies suggest that curcumin may delay disease progression rather than improve biomarkers and cognitive function. It is possible that poor bioavailability of curcumin, selection of cohorts at an advanced stage of AD, and differences in the biology of rodent models and AD patients may be responsible for these failures in clinical trials. It is interesting to note that one clinical trial combining curcumin and Bioperine was terminated, while another trial of high-bioavailability curcumin formulation (Longvida) was not updated, yet both had enhanced bioavailability of curcumin (Table 1). Additionally, to the best of our knowledge, none of the existing models fully reproduce the complete pathology and process of AD. Many interventions, although successful in animal models, have failed in clinic trials (LaFerla and Green, 2012).This highlights the urgent need for a next-generation of animal models, which better recapitulate critical aspects of the disease spectrum and facilitate success in preclinical studies and human clinical trials. Thus, it is premature to conclude that there is no effect of curcumin in AD patients. More studies with better bioavailability and delivery strategies,larger numbers of patients at the asymptomatic stage, and longer treatment durations are highly desirable.

    Pharmacokinetic Studies and Commercial Formulations

    Curcumin is soluble in organic solvents, but insoluble in water (Wang et al., 1997). Although curcumin is safe and well-tolerated, absorption of curcumin is quite poor. Clinical studies in humans have shown that curcumin is generally safe even at high doses up to 8 g/d (Cheng et al., 2001),but with no detectable levels of the parent compound in the plasma unless patients ingest > 8 g (Lao et al., 2006). Moreover, curcumin availability is lower in the brain than other organs (Vareed et al., 2008). Curcumin undergoes extensive first-pass glucuronidation, resulting in rapid elimination in bile and urine (Ireson et al., 2001). Approximately 75%of curcumin can be detected in feces after a dietary dose (1 g/kg) administered to rats (Sharma et al., 2007). Similarly,curcumin declined rapidly and was unquantifiable within 3–6 hours after intake (Vareed et al., 2008). The main factors limiting curcumin bioavailability are low solubility, poor absorption, and rapid metabolism and elimination. Therefore,numerous studies have been directed at increasing curcumin bioavailability, including use of phospholipid complex formation, loading curcumin into liposomes and nanoparticle encapsulation, and intranasal administration (Table 2).

    Conclusions

    Curcumin is one of the most studied phytochemical agents in the spice turmeric, displaying complex and multifaceted activities. There have been many reports on curcumin and its roles in AD. This review highlights the unique photophysical, chemical, and biological activities of curcumin as well as its properties throughout the course of AD. It shows high-affinity binding to Aβ and a strong fluorescence signal, making it a powerful diagnostic tool for AD. Many curcumin tracers have been developed to assess Aβ deposits in vivo, including the18F curcumin derivatives, FMeCl and CRANAD-X. These probes have sufficiently long excitation and emission wavelengths for deep brain imaging, reasonable BBB permeability, low toxicity, and reasonable stability.Moreover, CRANAD-58 and CRANAD-3 can detect both soluble and insoluble Aβ species. Further, CRANAD-28 and FMeC1 play a dual role in imaging and therapy. There is concern that reduction of Aβ burden by curcumin derivatives may interfere with Aβ imaging. However, Aβ imaging is performed in the early hours after administration of curcumin derivatives, and its effect on Aβ levels is likely to be minimal at 6 months (Yanagisawa et al., 2011; Zhang et al., 2014). In contrast, prevention and treatment of Aβ requires long-term curcumin administration (Yanagisawa et al., 2015). Curcumin is abundant in an Asian-type diet and may reduce AD risk, consistent with lower AD prevalence in India. Evidence also suggests that curcumin consumption has diverse potential health benefits in the aged population.Apart from its role in diagnosis and prevention, curcumin acts in AD therapies as an antioxidant, anti-inflammatory agent, inhibitor of Aβ aggregation, and chelator of metal ions. Taken together, current research suggests that curcumin is one of the most promising and exciting compounds for development of AD therapeutics.

    To date, one clinical study has evaluated the sensitivity and specificity of curcumin fluorochrome in retinal Aβ imaging. This study obtained positive results and has encouraged more clinical trials of curcumin-related Aβ probes in brain imaging. Besides, curcumin shows potential beneficial effects on human health, which may reduce risk factors of AD, and make it a life-long anti-aging nutraceutical. Although curcumin has multifaceted biological activity in AD animal models, its treatment in AD patients remains a challenge, and development of early AD diagnosis and new curcumin formulations are an active area of research.

    Author contributions:All authors drafted/revised the paper, and approved the final version of the paper.

    Conflicts of interest:None declared.

    Financial support:This study was supported by a grant from the Department of Education of Guangdong Province of China, No. 2016KCXTD005. The funder had no involvement in the study design; data collection, analysis, and interpretation; paper writing; or decision to submit the paper for publication.

    Plagiarism check:Checked twice by iThenticate.

    Peer review:Externally peer reviewed.

    Open access statement:This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak,and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

    Ahmad W, Kumolosasi E, Jantan I, Bukhari SN, Jasamai M (2014) Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2, cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin e synthase-1. Chem Biol Drug Des 83:670-681.

    Ak T, Gül?in ? (2008) Antioxidant and radical scavenging properties of Curcumin. Chem Biol Interact 174:27-37.

    Alzheimer’s Association (2010) 2010 Alzheimer’s disease facts and figures. Alzheimer’s Dement 6:158-194.

    Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11:332-384.

    Araujo C, Leon L (2001) Biological activities of curcuma longa L. Mem Inst Oswaldo Cruz 96:723-728.

    Arun N, Nalini N (2002) Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 57:41-52.

    Ataie A, Sabetkasaei M, Haghparast A, Moghaddam AH, Kazeminejad B(2010) Neuroprotective effects of the polyphenolic antioxidant agent,curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav 96:378-385.

    Bajda M, Guzior N, Ignasik M, Malawska B (2011) Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 18:4949-4975.

    Banerjee R (2014) Effect of curcumin on the metal ion induced fibrillization of amyloid-β peptide. Spectrochim Acta Part A 117:798-800.

    Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC,Marcus DS, Cairns NJ, Xie X, Blazey TM (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795-804.

    Baum L, Lam CWK, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V,Hui E, Ng C (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110-113.

    Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso AdC(2014) Tau-induced neurodegeneration: mechanisms and targets.Neurosci Bull 30:346-358.

    Belkacemi A, Doggui S, Dao L, Ramassamy C (2011) Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 13:e34.

    Belviranl? M, Okudan N, Atal?k KEN, ?z M (2013) Curcumin improves spatial memory and decreases oxidative damage in aged female rats.Biogerontology 14:187-196.

    Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88:1337-1342.

    Broussard GJ, Mytar J, Li RC, Klapstein GJ (2012) The role of inflammatory processes in Alzheimer’s disease. Inflammopharmacology 20:109-126.

    Chase A (2014) Alzheimer disease: advances in imaging of AD biomarkers could aid early diagnosis. Nat Rev Neurol 10:239-239.

    Chen X, Zhi F, Jia X, Zhang X, Ambardekar R, Meng Z, Paradkar AR,Hu Y, Yang Y (2013) Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol 65:807-816.

    Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT,Lin BR, Ming-Shiang W (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900.

    Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L (2013)Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J 15:324-336.

    Cheng KK, Chan PS, Fan S, Kwan SM, Yeung KL, Wáng Y-XJ, Chow AHL, Wu EX, Baum L (2015) Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials 44:155-172.

    Condello C, Schain A, Grutzendler J (2011) Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep 1:19.

    Cox KH, Pipingas A, Scholey AB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29:642-651.

    Cui M, Ono M, Kimura H, Liu B, Saji H (2011) Synthesis and structure?affinity relationships of novel dibenzylideneacetone derivatives as probes for β-amyloid plaques. J Med Chem 54:2225-2240.

    DiSilvestro RA, Joseph E, Zhao S, Bomser J (2012) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11:79.

    Dkhar P, Sharma R (2010) Effect of dimethylsulphoxide and curcumin on protein carbonyls and reactive oxygen species of cerebral hemispheres of mice as a function of age. Int J Dev Neurosci 28:351-357.

    Dong S, Zeng Q, Mitchell ES, Xiu J, Duan Y, Li C, Tiwari JK, Hu Y, Cao X, Zhao Z (2012) Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One 7:e31211.

    Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P,Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G (2007)Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 6:734-746.

    Fang M, Chen D, Yang CS (2007) Dietary polyphenols may affect DNA methylation. J Nutr 137:223S-228S.

    Frautschy SA, Cole GM (2010) Why pleiotropic interventions are needed for Alzheimer’s disease. Mol Neurobiol 41:392-409.

    Frost S, Kanagasingam Y, Macaulay L, Koronyo-Hamaoui M, Koronyo Y, Biggs D, Verdooner S, Black K, Taddei K, Shah T (2014) Retinal amyloid fluorescence imaging predicts cerebral amyloid burden and alzheimer’s disease. Alzheimers Dement 10:P234-P235.

    Fux R, Kloor D, Hermes M, R?ck T, Proksch B, Grenz A, Delabar U,Bücheler R, Igel S, M?rike K (2005) Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. Am J Physiol Renal Physiol 289:F786-792.

    Garcia-Alloza M, Borrelli L, Rozkalne A, Hyman B, Bacskai B (2007)Curcumin labels amyloid pathology in vivo, disrupts existing plaques,and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095-1104.

    Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V,Molinaro G, Pappalardo G, Messina A, Palmigiano A (2009) β-amyloid monomers are neuroprotective. J Neurosci 29:10582-10587.

    Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918-934.

    Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787-809.

    Gong Z, Zhou J, Li H, Gao Y, Xu C, Zhao S, Chen Y, Cai W, Wu J (2015)Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res 59:2132-2142.

    Goozee K, Shah T, Sohrabi HR, Rainey-Smith S, Brown B, Verdile G,Martins R (2016) Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br J Nutr 115:449-465.

    Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:195-218.

    Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163:1524-1528.

    Hagl S, Kocher A, Schiborr C, Kolesova N, Frank J, Eckert GP (2015)Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice–Impact on bioavailability. Neurochem Int 89:234-242.

    Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Fr?lich L, Riepe MW, Dodel R, Leyhe T, Bertram L (2011) The future of Alzheimer’s disease: the next 10 years. Prog Neurobiol 95:718-728.

    He Y, Yue Y, Zheng X, Zhang K, Chen S, Du Z (2015) Curcumin, inflammation, and chronic diseases: how are they linked? Molecules 20:9183-9213.

    Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, Frautschy SA (2015)Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 15:629-637.

    Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204-1222.

    Innamorato NG, Rojo AI, García-Yagüe áJ, Yamamoto M, De Ceballos ML, Cuadrado A (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181:680-689.

    Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L,Plummer S, Jukes R, Williams M (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61:1058-1064.

    Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108:5819-5824.

    Jorm AF (2001) History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry 35:776-781.

    Kim M, Kim Y (2010) Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet.Nutr Res Pract 4:191-195.

    Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, Chung HY,Mattson MP, Lee J (2008) Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 283:14497-14505.

    Kozmon S, Tvaro?ka I (2015) Molecular dynamic studies of amyloid-beta interactions with curcumin and Cu2+ions. Chem Papers 69:1262-1276.

    Kundaikar HS, Degani MS (2015) Insights into the Interaction mechanism of ligands with Aβ42 based on molecular dynamics simulations and mechanics: implications of role of common binding site in drug design for alzheimer’s disease. Chem Biol Drug Des 86:805-812.

    Kuo YC, Lin CC (2015) Rescuing apoptotic neurons in Alzheimer’s disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated nerve growth factor and curcumin. Int J Nanomedicine 10:2653.

    LaFerla FM, Green KN (2012) Animal models of Alzheimer disease.Cold Spring Harb Perspect Med 2:a006320.

    Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM,Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10.

    Li Y, Li J, Li S, Li Y, Wang X, Liu B, Fu Q, Ma S (2015) Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol Appl Pharmacol 286:53-63.

    Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L (2010) The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 485:83-88.

    Lopez OL (2011) The growing burden of Alzheimer’s disease. Am J Manag Care 17:S339-345.

    Luque-Contreras D, Carvajal K, Toral-Rios D, Franco-Bocanegra D,Campos-Pe?a V (2014) Oxidative stress and metabolic syndrome:cause or consequence of Alzheimer’s disease? Oxid Med Cell Longev 2014: 497802.

    Maiti P, Rossignol J, Dunbar G (2017) Curcumin modulates molecular chaperones and autophagy-lysosomal pathways in vitro after exposure to Aβ42. J Alzheimer Dis Parkinsonism 7:299.

    Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One 7:e32616.

    Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 42:423-432.

    McClure R, Yanagisawa D, Stec D, Abdollahian D, Koktysh D, Xhillari D, Jaeger R, Stanwood G, Chekmenev E, Tooyama I (2015) Inhalable curcumin: offering the potential for translation to imaging and treatment of Alzheimer’s disease. J Alzheimers Dis 44:283-295.

    Meng F, Asghar S, Gao S, Su Z, Song J, Huo M, Meng W, Ping Q, Xiao Y (2015) A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer’s disease. Colloids Surf B Biointerfaces 134:88-97.

    Metaxas A, Kempf SJ (2016) Neurofibrillary tangles in Alzheimer’s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res 11:1579-1581.

    Mohorko N, Repov? G, Popovi? M, Kovacs GG, Bresjanac M (2010)Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol 69:405-414.

    Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG(2014) Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem 80:175-183.

    Nahar PP, Slitt AL, Seeram NP (2015) Anti-inflammatory effects of novel standardized solid lipid curcumin formulations. J Med Food 18:786-792.

    Nasir Abbas Bukhari S, Jantan I (2015) Synthetic curcumin analogs as inhibitors of β-amyloid peptide aggregation: potential therapeutic and diagnostic agents for Alzheimer’s disease. Mini Rev Med Chem 15:1110-1121.

    Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164:898-906.

    Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s β-amyloid fibrils in vitro. J Neurosci Res 75:742-750.

    Park K, Seo Y, Kim MK, Kim K, Kim YK, Choo H, Chong Y (2015)A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer’s disease. Org Biomol Chem 13:11194-11199.

    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P (2006) Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers.Mech Ageing Dev 127:129-132.

    Parr C, Mirzaei N, Christian M, Sastre M (2015) Activation of the Wnt/β-catenin pathway represses the transcription of the β-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. FASEB J 29:623-635.

    Patil R, Gangalum PR, Wagner S, Portilla-Arias J, Ding H, Rekechenetskiy A, Konda B, Inoue S, Black KL, Ljubimova JY (2015) Curcumin targeted, polymalic acid-based MRI contrast agent for the detection of Aβ plaques in Alzheimer’s disease. Macromol Biosci 15:1212-1217.

    Perrone L, Mothes E, Vignes M, Mockel A, Figueroa C, Miquel MC,Maddelein ML, Faller P (2010) Copper transfer from Cu–Aβ to human serum albumin inhibits aggregation, radical production and reduces Aβ toxicity. Chembiochem 11:110-118.

    Pinkaew D, Changtam C, Tocharus C, Thummayot S, Suksamrarn A,Tocharus J (2015) Di-O-demethylcurcumin protects SK-N-SH cells against mitochondrial and endoplasmic reticulum-mediated apoptotic cell death induced by Aβ25-35. Neurochem Int 80:110-119.

    Priyadarsini KI (2009) Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol C 10:81-95.

    Ran C, Xu X, Raymond SB, Ferrara BJ, Neal K, Bacskai BJ, Medarova Z,Moore A (2009) Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J Am Chem Soc 131:15257-15261.

    Rao PP, Mohamed T, Teckwani K, Tin G (2015) Curcumin binding to beta amyloid: a computational study. Chem Biol Drug Des 86:813-820.

    Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc?) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. J Alzheimers Dis 23:61-77.

    Reinke AA, Gestwicki JE (2007) Structure–activity Relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 70:206-215.

    Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7:137-152.

    Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M,Gylys KH, Badmaev V, Heath DD, Apostolova LG (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers ResTher 4:43.

    Rinwa P, Kumar A, Garg S (2013) Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLoS One 8:e61052.

    Rokka J, Snellman A, Zona C, La Ferla B, Nicotra F, Salmona M, Forloni G, Haaparanta-Solin M, Rinne JO, Solin O (2014) Synthesis and evaluation of a18F-curcumin derivate for β-amyloid plaque imaging.Bioorg Med Chem 22:2753-2762.

    Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT (2006) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging. J Med Chem 49:6111-6119.

    Safouris A, Tsivgoulis G, N Sergentanis T, Psaltopoulou T (2015) Mediterranean diet and risk of dementia. Curr Alzheimer Res 12:736-744.

    Sharma RA, Steward WP, Gescher AJ (2007) Pharmacokinetics and pharmacodynamics of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Biol 10:81-95.

    Shi X, Zheng Z, Li J, Xiao Z, Qi W, Zhang A, Wu Q, Fang Y (2015)Curcumin inhibits Aβ-induced microglial inflammatory responses in vitro: involvement of ERK1/2 and p38 signaling pathways. Neurosci Lett 594:105-110.

    Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, Zhai G (2011) Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 354:116-123.

    Soni K, Kuttan R (1992) Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36:273-273.

    Soto C (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer’s disease. Mol Med Today 5:343-350.

    Soudamini K, Unnikrishnan M, Soni K, Kuttan R (1992) Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol 36:239-239.

    Tsai YM, Chien CF, Lin LC, Tsai TH (2011) Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 416:331-338.

    Tu P, Fu H, Cui M (2015) Compounds for imaging amyloid-β deposits in an Alzheimer’s brain: a patent review. Expert Opin Ther Pat 25:413-423.

    Valera E, Dargusch R, Maher PA, Schubert D (2013) Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer’s disease. J Neurosci 33:10512-10525.

    Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z,Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17:1411-1417.

    Verma M, Vats A, Taneja V (2015) Toxic species in amyloid disorders:oligomers or mature fibrils. Ann Indian Acad Neurol 18:138.

    Vivar C (2015) Adult hippocampal neurogenesis, aging and neurodegenerative diseases: possible strategies to prevent cognitive impairment. Curr Top Med Chem 15:2175-2192.

    Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, Tang HD, Ding JQ, Chen SD (2010) PPARγ agonist curcumin reduces the amyloid-β-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20:1189-1199.

    Wang X, Kim JR, Lee SB, Kim YJ, Jung MY, Kwon HW, Ahn YJ (2014)Effects of curcuminoids identified in rhizomes of Curcuma longa on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer’s disease drosophila models. BMC Complement Altern Med 14:88.

    Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK (1997)Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867-1876.

    Wang Y, Yin H, Wang L, Shuboy A, Lou J, Han B, Zhang X, Li J (2013)Curcumin as a potential treatment for Alzheimer’s disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. Am J Chin Med 41:59-70.

    Wanninger S, Lorenz V, Subhan A, Edelmann FT (2015) Metal complexes of curcumin–synthetic strategies, structures and medicinal applications. Chem Soc Rev 44:4986-5002.

    Wu A, Noble EE, Tyagi E, Ying Z, Zhuang Y, Gomez-Pinilla F (2015)Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders. Biochim Biophys Acta 1852:951-961.

    Yamada M, Ono K, Hamaguchi T, Noguchi-Shinohara M (2015) Natural phenolic compounds as therapeutic and preventive agents for cerebral amyloidosis. Adv Exp Med Biol 863:79-94.

    Yan SD, Chen X, Fu J, Chen M (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382:685.

    Yanagisawa D, Ibrahim NF, Taguchi H, Morikawa S, Hirao K, Shirai N,Sogabe T, Tooyama I (2015) Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiol Aging 36:201-210.

    Yanagisawa D, Amatsubo T, Morikawa S, Taguchi H, Urushitani M,Shirai N, Hirao K, Shiino A, Inubushi T, Tooyama I (2011) In vivo detection of amyloid β deposition using19F magnetic resonance imaging with a19F-containing curcumin derivative in a mouse model of Alzheimer’s disease. Neuroscience 184:120-127.

    Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS,Chen PP, Kayed R, Glabe CG, Frautschy SA (2005) Curcumin inhibits formation of amyloid β oligomers and fi brils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901.

    Ye S, Wang TT, Cai B, Wang Y, Li J, Zhan JX, Shen GM (2017) Genistein protects hippocampal neurons against injury by regulating calcium/calmodulin dependent protein kinase IV protein levels in Alzheimer’s disease model rats. Neural Regen Res 12:1479-1484.

    Youn HS, Saitoh SI, Miyake K, Hwang DH (2006) Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 72:62-69.

    Zhang X, Yin WK, Shi XD, Li Y (2011) Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Eur J Pharm Sci 42:540-546.

    Zhang X, Tian Y, Li Z, Tian X, Sun H, Liu H, Moore A, Ran C (2013)Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer’s disease. J Am Chem Soc 135:16397-16409.

    Zhang X, Tian Y, Yuan P, Li Y, Yaseen MA, Grutzendler J, Moore A,Ran C (2014) A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer’s disease. Chem Commun (Camb) 50:11550-11553.

    Zhang X, Tian Y, Zhang C, Tian X, Ross AW, Moir RD, Sun H, Tanzi RE,Moore A, Ran C (2015) Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. Proc Natl Acad Sci U S A 112:9734-9739.

    猜你喜歡
    履歷表小景段位
    春節(jié)小景
    ——豐子愷漫畫作品欣賞
    聯(lián)覺段位:中國新詩的有機(jī)性敘事
    “復(fù)興號”美食“新段位”
    生命的源泉
    ——趵突小景
    林中小景
    履歷表格這樣填
    測測你是哪個(gè)段位的吃貨
    網(wǎng)紅履歷表
    春日小景
    創(chuàng)客,你是什么段位?
    新民周刊(2015年18期)2015-09-10 07:22:44
    国产亚洲精品久久久久久毛片| 亚洲第一青青草原| av视频在线观看入口| 国产精华一区二区三区| www.精华液| 国产精品亚洲美女久久久| 12—13女人毛片做爰片一| 一进一出好大好爽视频| 亚洲国产精品成人综合色| 人人妻人人澡人人看| a在线观看视频网站| 国产成人av教育| 夜夜躁狠狠躁天天躁| 777久久人妻少妇嫩草av网站| 久久久久亚洲av毛片大全| 国产精品九九99| 两性夫妻黄色片| 日本在线视频免费播放| 欧美不卡视频在线免费观看 | 国产视频一区二区在线看| 亚洲国产精品999在线| 成人亚洲精品一区在线观看| 国产麻豆69| 人妻丰满熟妇av一区二区三区| 一级a爱视频在线免费观看| 97碰自拍视频| 亚洲av电影在线进入| 午夜精品久久久久久毛片777| 九色国产91popny在线| av免费在线观看网站| 美女免费视频网站| 69av精品久久久久久| 国产单亲对白刺激| 欧美精品啪啪一区二区三区| 在线观看一区二区三区| 国产成人精品久久二区二区91| 夜夜夜夜夜久久久久| 亚洲av成人一区二区三| 亚洲欧美日韩无卡精品| 两个人视频免费观看高清| 精品免费久久久久久久清纯| 亚洲欧美激情综合另类| 成人18禁在线播放| 久久精品国产综合久久久| 97碰自拍视频| 99精品欧美一区二区三区四区| 亚洲精品美女久久久久99蜜臀| 中文字幕精品免费在线观看视频| 9191精品国产免费久久| 国产精品一区二区免费欧美| 精品高清国产在线一区| 777久久人妻少妇嫩草av网站| 99国产极品粉嫩在线观看| 精品国产一区二区三区四区第35| 99热只有精品国产| 日韩欧美免费精品| 午夜免费激情av| 最新在线观看一区二区三区| 最新美女视频免费是黄的| 精品国产国语对白av| 曰老女人黄片| 日韩免费av在线播放| 午夜福利欧美成人| 国产一区二区在线av高清观看| 国产成人精品无人区| 欧美色视频一区免费| 操美女的视频在线观看| 日韩欧美国产在线观看| 香蕉久久夜色| 亚洲精品中文字幕在线视频| 色在线成人网| 人人妻人人爽人人添夜夜欢视频| 黑丝袜美女国产一区| 亚洲精华国产精华精| a在线观看视频网站| 日韩有码中文字幕| 91麻豆av在线| 国产1区2区3区精品| 美女国产高潮福利片在线看| 国产精品综合久久久久久久免费 | 亚洲av成人av| 国产精品九九99| 电影成人av| 一进一出抽搐动态| 亚洲天堂国产精品一区在线| 成人国产综合亚洲| 中文字幕人妻丝袜一区二区| 日本撒尿小便嘘嘘汇集6| 黑人操中国人逼视频| 最好的美女福利视频网| 丝袜美腿诱惑在线| 久久伊人香网站| 又紧又爽又黄一区二区| 人人妻人人爽人人添夜夜欢视频| 国内精品久久久久久久电影| 岛国在线观看网站| 99热只有精品国产| 亚洲人成伊人成综合网2020| 又黄又爽又免费观看的视频| 亚洲第一青青草原| 极品人妻少妇av视频| 欧美乱码精品一区二区三区| 丁香欧美五月| 母亲3免费完整高清在线观看| svipshipincom国产片| 又紧又爽又黄一区二区| 成人免费观看视频高清| 91麻豆av在线| 亚洲中文字幕日韩| 十八禁网站免费在线| 亚洲人成电影免费在线| 亚洲国产日韩欧美精品在线观看 | 丝袜美腿诱惑在线| 亚洲精品国产色婷婷电影| 女同久久另类99精品国产91| 亚洲伊人色综图| 男女午夜视频在线观看| avwww免费| 久久精品影院6| 俄罗斯特黄特色一大片| 母亲3免费完整高清在线观看| 国产av一区在线观看免费| 亚洲中文字幕日韩| 久久中文字幕人妻熟女| 美女扒开内裤让男人捅视频| 色哟哟哟哟哟哟| 女生性感内裤真人,穿戴方法视频| aaaaa片日本免费| 欧美乱色亚洲激情| 久久精品国产亚洲av香蕉五月| 嫁个100分男人电影在线观看| 夜夜躁狠狠躁天天躁| 久久性视频一级片| 波多野结衣巨乳人妻| 午夜免费成人在线视频| 亚洲精华国产精华精| 欧美一级a爱片免费观看看 | 亚洲一区二区三区色噜噜| 国产欧美日韩精品亚洲av| 精品无人区乱码1区二区| 欧美性长视频在线观看| 午夜福利,免费看| bbb黄色大片| 国产熟女xx| 亚洲全国av大片| 久久精品国产亚洲av香蕉五月| 国产精品久久久人人做人人爽| 免费看美女性在线毛片视频| 亚洲一码二码三码区别大吗| 女警被强在线播放| 91老司机精品| 麻豆成人av在线观看| 国产亚洲精品第一综合不卡| 日韩三级视频一区二区三区| 成人手机av| 亚洲av电影不卡..在线观看| 欧美日本视频| 纯流量卡能插随身wifi吗| 宅男免费午夜| 免费看十八禁软件| 亚洲av电影不卡..在线观看| 在线十欧美十亚洲十日本专区| 精品人妻在线不人妻| 真人一进一出gif抽搐免费| 亚洲国产日韩欧美精品在线观看 | 人成视频在线观看免费观看| 中文字幕久久专区| 亚洲片人在线观看| 操出白浆在线播放| 亚洲最大成人中文| 欧美黄色片欧美黄色片| 91麻豆av在线| 亚洲全国av大片| 满18在线观看网站| 一级毛片高清免费大全| 国产精品久久久人人做人人爽| 69精品国产乱码久久久| 一二三四在线观看免费中文在| 久久久水蜜桃国产精品网| 国产区一区二久久| 一级黄色大片毛片| 国产精品精品国产色婷婷| 色尼玛亚洲综合影院| 纯流量卡能插随身wifi吗| а√天堂www在线а√下载| 久久人妻av系列| 伊人久久大香线蕉亚洲五| 欧美在线一区亚洲| 免费观看精品视频网站| 天天躁狠狠躁夜夜躁狠狠躁| 欧美色视频一区免费| 欧美绝顶高潮抽搐喷水| 久久天堂一区二区三区四区| 亚洲一区高清亚洲精品| 国产亚洲精品久久久久久毛片| 淫秽高清视频在线观看| 国产日韩一区二区三区精品不卡| 国产真人三级小视频在线观看| 香蕉国产在线看| 亚洲专区字幕在线| 久久久水蜜桃国产精品网| 99久久综合精品五月天人人| 日韩欧美国产一区二区入口| 国产av又大| 亚洲专区字幕在线| 久久久久久久午夜电影| 亚洲欧美精品综合久久99| 亚洲中文字幕日韩| 一个人观看的视频www高清免费观看 | 丝袜美足系列| 国产精品免费一区二区三区在线| 亚洲欧美激情综合另类| 欧美成人午夜精品| 51午夜福利影视在线观看| 亚洲九九香蕉| 免费观看精品视频网站| 日本a在线网址| 十八禁人妻一区二区| 在线观看免费日韩欧美大片| 亚洲一码二码三码区别大吗| 国产精品 国内视频| 精品一区二区三区四区五区乱码| 又黄又爽又免费观看的视频| 亚洲,欧美精品.| 国产国语露脸激情在线看| 少妇熟女aⅴ在线视频| 国产欧美日韩一区二区三| 成人手机av| 精品高清国产在线一区| 两个人免费观看高清视频| 91成年电影在线观看| 久热这里只有精品99| 欧美大码av| 国产单亲对白刺激| 欧美人与性动交α欧美精品济南到| 久久久久九九精品影院| 国产精品九九99| 一区福利在线观看| 午夜福利免费观看在线| 电影成人av| 国产欧美日韩综合在线一区二区| 亚洲国产精品久久男人天堂| 日日摸夜夜添夜夜添小说| 精品不卡国产一区二区三区| 午夜影院日韩av| www.999成人在线观看| 夜夜爽天天搞| 久久这里只有精品19| 国产高清videossex| 大型黄色视频在线免费观看| 日韩大码丰满熟妇| 欧美性长视频在线观看| 成人亚洲精品一区在线观看| 黄片播放在线免费| 久热这里只有精品99| 精品无人区乱码1区二区| 亚洲精品一卡2卡三卡4卡5卡| 国产一区二区在线av高清观看| 精品欧美一区二区三区在线| 日韩欧美国产一区二区入口| 如日韩欧美国产精品一区二区三区| 一本大道久久a久久精品| 国产成年人精品一区二区| 国产单亲对白刺激| av天堂在线播放| 在线观看午夜福利视频| www日本在线高清视频| 亚洲精品美女久久av网站| 国产亚洲欧美精品永久| 国产亚洲精品第一综合不卡| 亚洲人成电影免费在线| 亚洲中文字幕日韩| 亚洲五月色婷婷综合| 日韩欧美免费精品| 国产激情欧美一区二区| 91麻豆精品激情在线观看国产| av片东京热男人的天堂| 老熟妇仑乱视频hdxx| 一级片免费观看大全| 国产激情欧美一区二区| 99精品欧美一区二区三区四区| 成年女人毛片免费观看观看9| 身体一侧抽搐| 男人的好看免费观看在线视频 | 99精品在免费线老司机午夜| 欧美不卡视频在线免费观看 | 18禁黄网站禁片午夜丰满| 黄色a级毛片大全视频| 91九色精品人成在线观看| 一边摸一边做爽爽视频免费| 天天躁狠狠躁夜夜躁狠狠躁| 在线视频色国产色| 91精品三级在线观看| 国产精品久久久久久人妻精品电影| 久久香蕉激情| 制服人妻中文乱码| 欧美不卡视频在线免费观看 | 成人亚洲精品av一区二区| 午夜福利影视在线免费观看| 国产欧美日韩一区二区三区在线| 中文字幕人妻丝袜一区二区| 桃红色精品国产亚洲av| 中出人妻视频一区二区| 悠悠久久av| 色精品久久人妻99蜜桃| 成人国产综合亚洲| av视频在线观看入口| 黑人操中国人逼视频| 国产精品一区二区三区四区久久 | 精品国产乱子伦一区二区三区| 久久狼人影院| 老司机午夜福利在线观看视频| 999久久久国产精品视频| 久久久久国内视频| 国产精品98久久久久久宅男小说| 满18在线观看网站| 少妇熟女aⅴ在线视频| 日韩视频一区二区在线观看| 91精品国产国语对白视频| 国产91精品成人一区二区三区| 91麻豆av在线| 亚洲欧美日韩无卡精品| 首页视频小说图片口味搜索| 日本五十路高清| 操出白浆在线播放| 99久久久亚洲精品蜜臀av| 视频在线观看一区二区三区| 麻豆成人av在线观看| 亚洲欧美一区二区三区黑人| 久久精品亚洲精品国产色婷小说| 久久中文字幕人妻熟女| 搡老熟女国产l中国老女人| 亚洲精品美女久久av网站| 两个人看的免费小视频| 亚洲成人国产一区在线观看| 久久人妻av系列| 国产又色又爽无遮挡免费看| 成年女人毛片免费观看观看9| 午夜免费成人在线视频| 亚洲人成伊人成综合网2020| 久久人人97超碰香蕉20202| 亚洲成av人片免费观看| 国产一区二区三区视频了| 麻豆av在线久日| 亚洲国产精品合色在线| а√天堂www在线а√下载| 亚洲午夜理论影院| 一个人免费在线观看的高清视频| 一级毛片高清免费大全| 亚洲人成77777在线视频| 亚洲色图综合在线观看| 久久久久久国产a免费观看| 免费观看精品视频网站| 啦啦啦 在线观看视频| 久久热在线av| 欧美黄色片欧美黄色片| xxx96com| 亚洲av成人av| 久久青草综合色| 亚洲av美国av| 淫妇啪啪啪对白视频| 亚洲视频免费观看视频| av天堂久久9| 久久精品aⅴ一区二区三区四区| 老司机午夜福利在线观看视频| 亚洲美女黄片视频| 亚洲第一欧美日韩一区二区三区| 国产成人系列免费观看| 精品欧美一区二区三区在线| 午夜a级毛片| 欧美日韩亚洲国产一区二区在线观看| 久久亚洲精品不卡| 欧美国产日韩亚洲一区| 免费av毛片视频| 国产成人啪精品午夜网站| 国产一区在线观看成人免费| 午夜福利成人在线免费观看| 国产精品香港三级国产av潘金莲| 亚洲国产精品久久男人天堂| 午夜免费观看网址| 久久国产精品人妻蜜桃| 亚洲成av片中文字幕在线观看| 久久久久久久久免费视频了| 亚洲熟妇熟女久久| 国产1区2区3区精品| 99在线人妻在线中文字幕| 高潮久久久久久久久久久不卡| 免费在线观看完整版高清| 中文字幕最新亚洲高清| 免费在线观看完整版高清| 国产精品一区二区免费欧美| 亚洲熟妇中文字幕五十中出| 啦啦啦韩国在线观看视频| 久久久水蜜桃国产精品网| 日韩大尺度精品在线看网址 | 亚洲专区字幕在线| 国产成人精品久久二区二区91| 超碰成人久久| 国产成人精品久久二区二区91| 美女国产高潮福利片在线看| 国产精品 国内视频| 侵犯人妻中文字幕一二三四区| 电影成人av| 亚洲五月色婷婷综合| 午夜免费激情av| 午夜两性在线视频| 国产av又大| 亚洲精品中文字幕在线视频| 中文字幕人妻熟女乱码| 韩国精品一区二区三区| 国产区一区二久久| 亚洲第一av免费看| 国产av一区在线观看免费| 宅男免费午夜| 精品国产乱子伦一区二区三区| 天堂√8在线中文| 丁香六月欧美| 久久久精品欧美日韩精品| 国产精品亚洲美女久久久| а√天堂www在线а√下载| 激情在线观看视频在线高清| 午夜福利在线观看吧| 一级黄色大片毛片| 给我免费播放毛片高清在线观看| 99久久久亚洲精品蜜臀av| 美女 人体艺术 gogo| 人人妻,人人澡人人爽秒播| 国产亚洲欧美98| 在线视频色国产色| 国产av一区在线观看免费| 亚洲男人天堂网一区| 中文字幕av电影在线播放| 久久久精品欧美日韩精品| 日韩国内少妇激情av| 大型av网站在线播放| 国产精品一区二区精品视频观看| 久久午夜亚洲精品久久| 国产精品影院久久| 中出人妻视频一区二区| 18禁国产床啪视频网站| 国内精品久久久久精免费| 久久久国产精品麻豆| 久久精品国产综合久久久| 亚洲七黄色美女视频| 欧美日韩精品网址| 午夜福利免费观看在线| 久久精品亚洲熟妇少妇任你| 免费看十八禁软件| 每晚都被弄得嗷嗷叫到高潮| 99久久精品国产亚洲精品| 久久精品国产亚洲av高清一级| 一本综合久久免费| 亚洲五月天丁香| 国产视频一区二区在线看| 99香蕉大伊视频| 此物有八面人人有两片| 中文字幕色久视频| 亚洲伊人色综图| 亚洲人成电影免费在线| 国产高清视频在线播放一区| 欧美日韩黄片免| 女生性感内裤真人,穿戴方法视频| 亚洲在线自拍视频| 亚洲激情在线av| 老司机福利观看| 成人三级黄色视频| 可以免费在线观看a视频的电影网站| 午夜免费成人在线视频| 日韩一卡2卡3卡4卡2021年| 色哟哟哟哟哟哟| 男人的好看免费观看在线视频 | 久久精品成人免费网站| www日本在线高清视频| 香蕉丝袜av| 精品国产国语对白av| 国产午夜精品久久久久久| 日韩欧美国产在线观看| 久久狼人影院| 国产单亲对白刺激| 男人舔女人的私密视频| 欧美乱妇无乱码| 国产精品99久久99久久久不卡| 成人手机av| 人人妻,人人澡人人爽秒播| 熟女少妇亚洲综合色aaa.| 日本精品一区二区三区蜜桃| 9191精品国产免费久久| 免费人成视频x8x8入口观看| 久久久久久免费高清国产稀缺| 国产麻豆成人av免费视频| 巨乳人妻的诱惑在线观看| 天堂影院成人在线观看| av有码第一页| 欧美不卡视频在线免费观看 | av网站免费在线观看视频| 国产一区二区三区视频了| 国产亚洲欧美98| 国产蜜桃级精品一区二区三区| 怎么达到女性高潮| 精品免费久久久久久久清纯| 精品国产超薄肉色丝袜足j| 久久久精品国产亚洲av高清涩受| 亚洲国产看品久久| 黄色a级毛片大全视频| 免费看美女性在线毛片视频| 少妇 在线观看| 欧美日韩福利视频一区二区| 免费少妇av软件| av天堂久久9| 亚洲人成77777在线视频| av免费在线观看网站| 免费在线观看黄色视频的| 国产成人系列免费观看| 黄色a级毛片大全视频| 精品国产乱码久久久久久男人| 一级a爱视频在线免费观看| 欧美人与性动交α欧美精品济南到| 在线视频色国产色| 亚洲在线自拍视频| 18禁美女被吸乳视频| 久久香蕉精品热| 免费在线观看亚洲国产| 午夜免费观看网址| 欧美乱码精品一区二区三区| a在线观看视频网站| 日本五十路高清| 国产人伦9x9x在线观看| 亚洲性夜色夜夜综合| av免费在线观看网站| 人人妻人人澡人人看| av在线播放免费不卡| 人妻丰满熟妇av一区二区三区| 亚洲九九香蕉| 精品国产亚洲在线| 亚洲一区高清亚洲精品| 美女高潮喷水抽搐中文字幕| 两性午夜刺激爽爽歪歪视频在线观看 | xxx96com| 国产黄a三级三级三级人| 亚洲av片天天在线观看| avwww免费| 国产av在哪里看| 成年女人毛片免费观看观看9| 涩涩av久久男人的天堂| 一个人观看的视频www高清免费观看 | 啪啪无遮挡十八禁网站| 欧美激情久久久久久爽电影 | 在线观看66精品国产| 成人手机av| 亚洲专区国产一区二区| tocl精华| 婷婷精品国产亚洲av在线| 亚洲人成伊人成综合网2020| 搡老岳熟女国产| 久久久久精品国产欧美久久久| 国产xxxxx性猛交| 在线播放国产精品三级| 1024香蕉在线观看| 国产成人免费无遮挡视频| 少妇裸体淫交视频免费看高清 | 高清黄色对白视频在线免费看| 手机成人av网站| 日韩大码丰满熟妇| 国产成人欧美| 操美女的视频在线观看| 一区二区三区激情视频| 国产精品美女特级片免费视频播放器 | 91成人精品电影| 欧美另类亚洲清纯唯美| 午夜福利,免费看| 精品一区二区三区av网在线观看| 久久精品国产清高在天天线| 9色porny在线观看| 88av欧美| 久久久久久久久中文| 高清黄色对白视频在线免费看| 国产精品亚洲一级av第二区| 1024视频免费在线观看| 久久精品91蜜桃| 免费不卡黄色视频| 国产在线观看jvid| 欧美另类亚洲清纯唯美| 中文字幕人妻丝袜一区二区| 91九色精品人成在线观看| a级毛片在线看网站| 午夜两性在线视频| 久99久视频精品免费| 国产野战对白在线观看| 精品日产1卡2卡| 少妇被粗大的猛进出69影院| 亚洲情色 制服丝袜| АⅤ资源中文在线天堂| 久久国产精品人妻蜜桃| 露出奶头的视频| 国产伦一二天堂av在线观看| 亚洲精华国产精华精| 国产欧美日韩一区二区三区在线| 97超级碰碰碰精品色视频在线观看| 国产主播在线观看一区二区| 精品一区二区三区av网在线观看| 免费高清在线观看日韩| 在线观看舔阴道视频| 夜夜爽天天搞| 纯流量卡能插随身wifi吗| 老司机福利观看| 亚洲熟妇中文字幕五十中出| 精品久久久久久久久久免费视频| 欧美日本中文国产一区发布| netflix在线观看网站| 91av网站免费观看| 一边摸一边抽搐一进一出视频| 久久久久国内视频| 天天躁夜夜躁狠狠躁躁| 精品日产1卡2卡| 91精品三级在线观看|